A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

Amita Patnaik,Michael S. Gordon,Frank Yung-Chin Tsai,Kyri Papadopoulous,Drew W. Rasco,S. Muralidhar Beeram,Siqing Fu,Filip Janku,Scott M. Hynes,Sushma R. Gundala,Melinda D. Willard,Wei Zhang,Aimee Bence Lin,David Sanghyun Hong

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

2018

Amita Patnaik
Michael S. Gordon
Frank Yung-Chin Tsai
Kyri Papadopoulous
Drew W. Rasco
S. Muralidhar Beeram
Siqing Fu
Filip Janku
Scott M. Hynes
Sushma R. Gundala
Melinda D. Willard
Wei Zhang
Aimee Bence Lin
David Sanghyun Hong

Purpose The phase I study characterized the safety, pharmacokinetics, anti-tumor activity, and recommended phase II dose/schedule of LY3164530 in patients with advanced or metastatic cancer.

Keywords:

Antibody
Cancer
Pharmacology
Cancer research
Medicine
Pharmacokinetics
Toxicity
Oncology
Adverse effect
Colorectal cancer
Internal medicine
Maculopapular rash
Hypokalemia
Epidermal growth factor receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations